The “Potsdam Days on Bioanalysis” 1-2 November in Potsdam-Golm/Germany provide an excellent international platform for researchers, clinicians, and entrepreneurs including healthcare startups to discuss potentials and hot topics in diagnostics and analytics. Key topics include major trends, recent developments, new areas of application, and future markets. The conference is organized by the Cluster Health Capital in cooperation with the FluType project, and Fraunhofer IZI-BB.
More often than not, the implementation of goal-oriented and profitable cooperations turns out to be quite a challenge. This is true in particular when it comes to innovative product developments in the fields of diagnostics and analytics. Typically, challenges include finding the right partners for cooperation, identifying transfer points, and interpreting results for a quick market launch.
Cooperations – a top agenda item
The scope of cooperations can range from new products to fostering and creating knowledge, expanding value chains, and connecting sales channels. Well-wielded cooperations may enhance success regarding corporate, market, and indeed society viewpoints. Therefore, the event will lead participants along the value chains of analytics and diagnostics. With stakeholders from all fields concerned coming together in Potsdam, opportunities for establishing and operating new cooperations will open up.
Presented by an internationally renowned innovation manager, aspects of visionary concepts, operating rules, as well as societal and political requirements take a central position in Potsdam-Golm. In addition to introducing specific innovations within diagnostics and bioanalysis, the focus will be on describing typical challenges in creating and operating cooperations. Speakers will provide deep insights into their projects. They will reveal what went well, what could be done better and what they wish for.
Challenges in developing IVD
From biomarker to detection devices to the final product: What are the challenges in the development of IVD along the value chain? The path from the discovery of the first biomarker to the final diagnostic device is long, and it includes many pitfalls that can terminate a project prematurely. The first part of the “Potsdam Days” is dedicated to this topic and shows how cooperation beyond the narrow limits of one’s own field can lead to new developments.
Quo vadis IVD?
In the context of new regulations and business models – in particular concerning the use and processing of large volumes of data – what are emerging challenges in diagnostics? Will value creation ten years from now still have its foundation in selling diagnostic systems, or will profit be derived rather from the processing of data? These questions will be discussed on the afternoon of November 1.
Infection Diseases: New challenges and innovative solutions
The availability of vaccines and antibiotics has had negative effects on the awareness of risks from infectious diseases. Today, due to vaccination fatigue, increasingly resistant pathogens, as well as worldwide passenger and goods traffic, the risk potential of new epidemics is on the increase, and infectious diseases move back into the focus of attention.
On November 2, the challenges of diagnosing infections are addressed, and new developments in detection devices will be presented. Also figuring on the agenda for that day will be the BB LIFE Seminar: “The new IVD-Regulation for Beginners and Specialists”.
The new IVD-Regulation affects the work of all players in the IVD sector: manufacturing companies, public authorities, producer associations, and notified bodies. Also Researchers and developers of IVD should also have a good idea of the new regulations regarding IVD certification and market access.
This seminar will provide an overview of the new regulation and the status of its realization. It will focus on the new classification system, the certification process, and the clinical evaluation for IVD. A wrap-up will deal with the consequences for the IVD-Industry.
Stakeholders with a dedicated, or potential, interest in in vitro diagnostics and point of care testing are invited to join this conference for new insights and for making the connections that matter.
The conference is funded by the State of Berlin and the State of Brandenburg as well as the Investitions- und Landesbank Brandenburg; it is co-funded by the European Union – European Regional Development Fund.
Quelle Foto: © REDPIXEL – fotolia.com